分层治疗晚期非小细胞肺癌160例

Significance and Clinical Value of Stratified Therapy for 160 Cases of Advanced Non-Small Cell Lung Cancer

目的:将分层治疗模式应用于晚期非小细胞肺癌(NSCLC)患者的治疗中,探讨其治疗意义及临床价值。方法:选取医院收治的NSCLC患者160例为研究对象,根据分层治疗原则,采取以化疗、放疗、靶向分子药物、中药扶正等综合治疗,观察近期疗效和远期疗效,分析远期疗效及其相关因素的关系。结果:160例患者中,有效率(RR)为70.0%(112/160),ⅢB组RR明显高于IV组(P<0.05);160例患者总生存期(OS)为(29.2±4.8)个月,无进展生存期(PFS)为(11.8±2.1)个月;患者KPS评分、TNM分期、病理类型、EGFR基因、放射治疗、靶向分子药物治疗与总生存期和无进展生存期呈显著相关性(P<0.05)。结论:分层治疗模式应用于晚期NSCLC患者的治疗中临床疗效显著,能为临床选择标准治疗方案提供可靠依据。

Objective:To discuss significance and clinical value of the stratified therapy in the treatment of advanced non-small cell lung cancer(NSCLC)patients Methods:160 cases of NSCLC patients in the Second People's Hospital of Jingdezhen had been selected as subjects.According to the principle of the stratified therapy,chemotherapy,radiotherapy,targeted molecular medicine,Chinese medicine and other integrated therapies had been used.The short-term and long-term effects had been observed and the long-term effects and related factors had been analyzed.Results:In 160 cases,RR was 70.0%,and RR in the group of IIIB was significantly higher than that in the group of IV(P <0.05);in 160 patients,OS was(29.2+4.8)months,PFS(11.8+2.1)months;KPS scores,TNM stages,pathological types,EGFR genes,radiation therapy and targeted molecular drug therapy were significantly correlated with total survival(OS)and progression free survival(PFS)(P<0.05).Conclusion:The stratified therapy is effective in the treatment of patients with advanced NSCLC.It can provide a reliable basis for clinical selection of standard treatment plans and has important clinical value.